Literature DB >> 32883618

Development and validation of prescription drug risk, efficacy, and benefit perception measures in the context of direct-to-consumer prescription drug advertising.

Bridget J Kelly1, Douglas J Rupert2, Kathryn J Aikin3, Helen W Sullivan3, Mihaela Johnson2, Carla M Bann2, Nicole Mack2, Brian G Southwell2, Sue West2, Sarah Parvanta2, Alexander Rabre2, Susana Peinado2.   

Abstract

PURPOSE: Understanding patient perceptions of prescription drug risks and benefits is an important component of determining risk-benefit tradeoffs and helping patients make informed medication decisions. However, few validated measures exist for capturing such perceptions. The purpose of this study was to develop and validate measures of perception of prescription drug risk, efficacy, and benefit.
METHODS: We conducted a mixed-methods study to develop and validate the measures, including three waves of quantitative testing (item nonresponse, criterion-related validity, and convergent validity). We conducted quantitative testing with a probability-based online consumer panel of U.S. adults (n = 7635), eliminating weaker items after each testing wave.
RESULTS: Upon completion of all testing, we identified 21 validated measures that represent 11 distinct risk/benefit constructs. The final measures demonstrated face validity, convergent validity, criterion-related validity, and scale reliability in both illness and general population samples, among patients with both symptomatic and asymptomatic health conditions, and in response to both television and print direct-to-consumer prescription drug advertisements.
CONCLUSIONS: Our study produced a set of items that researchers and practitioners can use to assess patient perceptions of prescription drug risk, benefit, and efficacy and to ensure greater future comparability between studies.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Efficacy perceptions; Measurement validation; Prescription drugs; Risk perceptions

Mesh:

Substances:

Year:  2020        PMID: 32883618      PMCID: PMC8842561          DOI: 10.1016/j.sapharm.2020.07.028

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  36 in total

1.  Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?

Authors:  C Lee Ventola
Journal:  P T       Date:  2011-10

2.  Efficacy vs effectiveness.

Authors:  Charlene Compher
Journal:  JPEN J Parenter Enteral Nutr       Date:  2010 Nov-Dec       Impact factor: 4.016

3.  The Medication Attribution Scale: perceived effects of antiretrovirals and quality of life.

Authors:  S Aversa; C Kimberlin; R Segal
Journal:  Qual Life Res       Date:  1998-04       Impact factor: 4.147

4.  What effects do patients feel from their antihypertensive tablets and how do they react to them? Qualitative analysis of interviews with patients.

Authors:  John Benson; Nicky Britten
Journal:  Fam Pract       Date:  2005-08-17       Impact factor: 2.267

5.  Validation of the revised Patient Perception of Migraine Questionnaire (PPMQ-R): measuring satisfaction with acute migraine treatment in clinical trials.

Authors:  M Kimel; R Hsieh; J McCormack; S P Burch; D A Revicki
Journal:  Cephalalgia       Date:  2008-03-31       Impact factor: 6.292

6.  Variability in Affect and Willingness to Take Medication.

Authors:  Liana Fraenkel; Marilyn Stolar; Jonathan R Bates; Richard L Street; Harjinder Chowdhary; Sarah Swift; Ellen Peters
Journal:  Med Decis Making       Date:  2017-08-30       Impact factor: 2.583

7.  The association between health beliefs and medication adherence among patients with type 2 diabetes.

Authors:  Yasser M Alatawi; Jan Kavookjian; Gladys Ekong; Meshari M Alrayees
Journal:  Res Social Adm Pharm       Date:  2015-11-22

8.  Intentional and Unintentional Medication Non-Adherence in Hypertension: The Role of Health Literacy, Empowerment and Medication Beliefs.

Authors:  Lilla Náfrádi; Elisa Galimberti; Kent Nakamoto; Peter J Schulz
Journal:  J Public Health Res       Date:  2016-12-21

9.  Direct-to-Consumer Promotion of Prescription Drugs on Mobile Devices: Content Analysis.

Authors:  Kathryn J Aikin; Helen W Sullivan; Suzanne Dolina; Molly Lynch; Linda B Squiers
Journal:  J Med Internet Res       Date:  2017-07-04       Impact factor: 5.428

10.  Assessing hearing and cognition challenges in consumer processing of televised risk information: Validation of self-reported measures using performance indicators.

Authors:  Brian G Southwell; Sarah A Parvanta; Mihaela M Johnson; Amie C O'Donoghue; Helen W Sullivan; Sarah E Ray; Cynthia S Soloe; Christine N Davis; Nancy McKenna
Journal:  Prev Med Rep       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.